La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Astena Holdings Résultats passés
Passé contrôle des critères 2/6
Astena Holdings's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 4.8% per year. Astena Holdings's return on equity is 7.2%, and it has net margins of 3.9%.
Informations clés
-13.5%
Taux de croissance des bénéfices
-18.1%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 3.4% |
Taux de croissance des recettes | -4.8% |
Rendement des fonds propres | 7.2% |
Marge nette | 3.9% |
Prochaine mise à jour des résultats | 11 Oct 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Astena Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 May 24 | 53,218 | 2,093 | 14,248 | 0 |
29 Feb 24 | 52,625 | 1,617 | 14,163 | 0 |
30 Nov 23 | 51,984 | 1,162 | 14,044 | 0 |
31 Aug 23 | 53,382 | 182 | 13,653 | 0 |
31 May 23 | 51,559 | -580 | 13,750 | 0 |
28 Feb 23 | 50,136 | -76 | 13,608 | 0 |
30 Nov 22 | 49,636 | 579 | 13,541 | 0 |
31 Aug 22 | 55,523 | 1,212 | 13,975 | 0 |
31 May 22 | 61,007 | 1,693 | 13,848 | 0 |
28 Feb 22 | 67,632 | 1,787 | 13,751 | 0 |
30 Nov 21 | 72,322 | 1,736 | 13,494 | 0 |
31 Aug 21 | 71,504 | 1,543 | 13,416 | 0 |
31 May 21 | 70,758 | 2,366 | 12,940 | 0 |
28 Feb 21 | 67,745 | 2,185 | 12,299 | 0 |
30 Nov 20 | 65,341 | 1,983 | 11,813 | 0 |
31 Aug 20 | 62,815 | 1,957 | 11,940 | 0 |
31 May 20 | 61,425 | 1,234 | 11,537 | 0 |
29 Feb 20 | 61,463 | 1,380 | 11,281 | 0 |
30 Nov 19 | 61,647 | 1,533 | 11,056 | 0 |
31 Aug 19 | 62,327 | 1,537 | 10,910 | 0 |
31 May 19 | 62,113 | 1,688 | 10,790 | 0 |
28 Feb 19 | 61,285 | 1,718 | 10,674 | 0 |
30 Nov 18 | 60,083 | 1,414 | 10,594 | 0 |
31 Aug 18 | 59,321 | 1,418 | 10,417 | 0 |
31 May 18 | 58,368 | 991 | 10,352 | 0 |
28 Feb 18 | 57,849 | 745 | 10,282 | 0 |
30 Nov 17 | 57,387 | 1,241 | 10,108 | 0 |
31 Aug 17 | 56,633 | 567 | 9,950 | 0 |
31 May 17 | 56,320 | 780 | 9,870 | 0 |
28 Feb 17 | 55,459 | 508 | 9,861 | 0 |
30 Nov 16 | 55,121 | 8 | 9,892 | 0 |
31 Aug 16 | 54,654 | 222 | 9,918 | 0 |
31 May 16 | 54,750 | -258 | 9,851 | 0 |
29 Feb 16 | 55,174 | -138 | 9,761 | 0 |
30 Nov 15 | 55,422 | -143 | 9,923 | 0 |
31 Aug 15 | 55,693 | 148 | 9,923 | 0 |
31 May 15 | 54,925 | 392 | 10,202 | 0 |
28 Feb 15 | 54,602 | 475 | 10,171 | 0 |
30 Nov 14 | 54,145 | 496 | 9,966 | 0 |
31 Aug 14 | 53,648 | 462 | 9,820 | 0 |
31 May 14 | 53,528 | 721 | 9,489 | 0 |
28 Feb 14 | 53,091 | 783 | 9,380 | 0 |
30 Nov 13 | 52,465 | 744 | 9,488 | 0 |
31 Aug 13 | 52,292 | 831 | 9,488 | 0 |
Des revenus de qualité: 8095 has high quality earnings.
Augmentation de la marge bénéficiaire: 8095 became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 8095's earnings have declined by 13.5% per year over the past 5 years.
Accélération de la croissance: 8095 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: 8095 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.6%).
Rendement des fonds propres
ROE élevé: 8095's Return on Equity (7.2%) is considered low.